ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO1114

Herpes Zoster and Disseminated Zoster in Lupus Nephritis: Incidence Rates in Real-World Claims Data

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Belendiuk, Katherine, Genentech, South San Francisco, California, United States
  • Ding, Yingjie, Genesis Research, Hoboken, New Jersey, United States
  • Chawla, Devika, Genentech, South San Francisco, California, United States
  • Cascino, Matthew, Genentech, South San Francisco, California, United States
Background

Herpes zoster is a highly morbid condition. Overall rates of herpes zoster in immunocompetent individuals in a claims database were 0.45 per 100 PY, with risk increasing with age [1]. Rates of herpes zoster and disseminated herpes zoster among patients with lupus nephritis (LN) have not previously been described. This study characterized rates of herpes zoster and disseminated zoster infections in patients with LN using population-based claims data.

Methods

We conducted a retrospective cohort study using the Truven Healthcare MarketScan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits database between 2000 and 2014. Patients with LN were identified using modifications to a validated claims data algorithm [2]. Herpes zoster cases were identified using ICD9 codes 053.xx. All patients received medical care in the U.S. and had 6 months of continuous medical and drug coverage ± first LN diagnosis (i.e. index). End of study was the first of end of enrollment or end of database.

Results

11,068 patients with LN were identified and followed for a mean of 6.8 years (Table). Among patients with LN there were 955 incident cases of herpes zoster events reported, of which 157 (16%) were considered disseminated. Incidence rates of herpes zoster and disseminated zoster were 2.6 (95% CI 2.4 to 2.7) and 0.4 (95% CI 0.3 to 0.5) per 100 PY, respectively.

Conclusion

Patients with LN appear to be at increased risk for herpes zoster relative to the general population. A substantial minority of LN patients with herpes zoster develop dissemination. Further characterization of the relative contributions of age, immunosuppressive therapies, and disease factors is warranted.

1. Johnson BH et al. BMC Infectious Diseases, 2015;15:502.
2. Chibnik LB et al. Lupus, 2010;19:741-3.

Funding

  • Commercial Support